Page 3 - Dry Amd News Today

Gene therapy is currently one of the trailblazing treatments for dry age-related macular degeneration under research.

There are at least ten ongoing clinical trials for stem cell therapies in vision loss. We will delve into one of the preclinical studies in this piece.

        Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023 ...

South Korea: A recent study published in Diabetes & Metabolism has reported an increased incidence of dry and wet age-related macular degeneration (AMD) in diabetes patients compared to those with...

Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents Paris, France, January 27, 2023 – 6.00 pm CET –...

A National Institutes of Health (NIH) surgical team implanted the first U.S. patient with a patch of tissue made from stem cells to treat AMD.

Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million. ...

Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti Paris, France, June 24, 2022 – 07:00 CET – Pixium...

        Pixium Vision announces its unaudited financial results for 2021 and provides a business update Cash position on 31 December 2021: €14.5...

Dry AMD is the largest cause of incurable blindness for people over 50 and affects nearly 170 million people worldwide